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BACKGROUND: Regulating cross-talk between anoikis and survival signaling pathways is crucial to regulating tissue processes and
mitigating diseases like cancer. Previously, the authors demonstrated that anoikis activates a signaling pathway involving the CD95/
Fas-mediated signaling pathway that is regulated by receptor-interacting protein (RIP), a kinase that shuttles between Fas-mediated
cell death and integrin/focal adhesion kinase (FAK)-mediated survival pathways. Because it is known that sirtuin-3 (SIRT3), a nicotin-
amide adenine dinucleotide-dependent deacetylase, regulates cell survival, metabolism, and tumorigenesis, the authors hypothesized
that SIRT3 may engage in cross-talk with Fas/RIP/integrin/FAK survival-death pathways in cancer cell systems. METHODS: Using im-
munohistochemical staining, immunoblotting, human tissue microarrays, and overexpression and suppression approaches in vitro and
in vivo, the roles of RIP and SIRT3 were examined in oral squamous cell carcinoma (OSCC) anoikis resistance and tumorigenesis.
RESULTS: RIP and SIRT3 had opposite expression profiles in OSCC cells and tissues. Stable suppression of RIP enhanced SIRT3 levels,
whereas stable suppression of SIRT3 did not impact RIP levels in OSCC cells. The authors observed that, as OSCC cells became anoi-
kis-resistant, they formed multicellular aggregates or oraspheres in suspension conditions, and their expression of SIRT3 increased as
their RIP expression decreased. Also, anoikis-resistant OSCC cells with higher SIRT3 and low RIP expression induced an increased tu-
mor burden and incidence in mice, unlike their adherent OSCC cell counterparts. Furthermore, stable suppression of SIRT3 inhibited
anoikis resistance and reduced tumor incidence. CONCLUSIONS: The current results indicted that RIP is a likely upstream, negative
regulator of SIRT3 in anoikis resistance, and an anoikis-resistant orasphere phenotype defined by higher SIRT3 and low RIP expres-
sion contributes to a more aggressive phenotype in OSCC development. Cancer 2012;118:5800-10. VC 2012 American Cancer
Society.
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INTRODUCTION
Anoikis—apoptotic cell death triggered by loss of extracellular matrix (ECM) contacts—is dysregulated in many chronic
debilitating and fatal diseases. Cancer cells evade apoptosis and possess self-sufficiency in growth signals: 2 important hall-
marks of cancer cells.1 Thus, cancer cells can evade apoptosis by escaping anoikis and becoming anoikis-resistant. Anoikis
resistance or anchorage-independent growth contributes to cancer development and progression.2-5 Although smoking,
alcohol consumption, and human papillomavirus (HPV) are risk factors for oral cancer, other factors that contribute to
tumorigenicity are poorly studied. One such factor, anoikis resistance, induces more aggressive tumors in oral squamous
cell carcinoma (OSCC).6-8
Oral cancer is 1 of the leading causes of death worldwide, and OSCC accounts for>90% of oral malignancies,9 yet
survival rates for oral cancer have not improved in decades. These disheartening statistics underscore the need to examine
its pathogenesis and to identify novel biomarkers and modes of therapy.
We recently demonstrated that receptor interacting protein (RIP), shuttles between the CD95/Fas death and focal
adhesion kinase (FAK) survival signaling pathways to mediate anoikis in OSCC cells.10 Hence, under anoikis conditions,
FAK and RIP dissociate, leading to the association of RIP with Fas (tumor necrosis factor receptor superfamily, member
6) and the formation of the death-inducing signaling complex, thus enhancing apoptosis. These findings support the de-
velopment of therapeutics that can target RIP as a switch to control cell death or survival pathways to ultimately regulate
normal tissue processes and tumorigenesis in cancer patients.
Sirtuins (SIRT1-SIRT7), the mammalian homologues of the Sir2 gene (nicotinamide adenine dinucleotide-depend-
ent deacetylase) in yeast, have an emerging role in regulating cellular processes and functions, including cell survival,
apoptosis, oxidative stress, development, metabolism, and aging.11,12 We recently reported that SIRT3, 1 of the
mitochondrial sirtuins,13-15 is overexpressed in OSCC cells and tissues compared with normal samples and that the
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down-regulation of SIRT3 in OSCC cells inhibited cell
growth and proliferation and increased the sensitivity of
those cells to both radiation therapy and chemotherapy.14
In addition, by using a floor-of-mouth oral cancer murine
model that mimics human OSCC,16,17 we demonstrated
that SIRT3 down-regulation reduced tumor burden in
vivo, implicating a prosurvival role for SIRT3 in oral can-
cer tumorigenesis.14 However, to our knowledge, the role
of SIRT3 in anoikis resistance has not been investigated.
Here, we reported for the first time a role for SIRT3 in
mediating anoikis resistance in oral cancer and its poten-
tial negative relation with RIP.
MATERIALS AND METHODS
Cell Lines and Culture
The human OSCC cell line HSC-3 was kindly provided
by Randy Kramer (University of California, San Fran-
cisco, Calif). The human OSCC cell line UM-SCC-14A
was a gift from Tom Carey (University of Michigan, Ann
Arbor, Mich). The poorly differentiated aggressive tongue
SCC cell line OSCC-3 was gift from Mark Lingen (Uni-
versity of Chicago, Chicago, Ill). OSCC cells were main-
tained in Dulbecco modified Eagle medium containing
10% fetal bovine serum, 1% penicillin, and 1% strepto-
mycin. Primary human oral keratinoctyes (ScienCell,
Carlsbad, Calif) were maintained in oral keratinocyte me-
dium (OKM; ScienCell, Carlsbad, Calif). RIP/ mouse
embryonic fibroblasts were kindly provided by Philip
Leder and Michelle Kellinger (Harvard Medical School,
Boston, Mass).
Tissue Microarrays
Immunohistochemical analyses were performed to deter-
mine the expression of SIRT3 and RIP in human OSCC
tissues using OSCC tissue microarrays (OR601 and
HN241; US Biomax, Inc., Rockville, Md) and the Histo-
statin Kit (95-6143; Zymed Laboratories, South San
Francisco, Calif) according to the manufacturer’s instruc-
tions. Antibodies to SIRT3 (AP6242a) and RIP
(610,459) were obtained from ABGENT (San Diego,
Calif), and Millipore (Billerica, Mass), respectively. We
recently reported that SIRT3 staining intensity was higher
in OSCC tongue samples14; and, because the tongue
accounts for approximately 30% of oral malignancies, we
specifically examined tongue samples in the current study.
Staining intensities for RIP and SIRT3 were graded in a
blinded manner by a pathologist. For RIP and SIRT3
assessment, the staining intensity and the percentage of
tumor cells stained were analyzed. Staining intensity was
scored as 1 (weak), 2 (moderate), or 3 (strong). Each core
also was evaluated for the percentage of tumor cells that
were stained positive (the staining proportion). A com-
bined score based on the staining intensity and the stain-
ing proportion was used to assign a final score. Low
expression was defined as an intensity of 1 or 2 and a stain-
ing proportion<10%, and high expression was defined as
an intensity 2 or 3 and a staining proportion>10%.
Transient Transfection
HSC-3 cells at 60% to 70% confluence were transiently
transfected with small interfering RNA (siRNA) (25 nM
or 50 nM) against RIP or with a nontargeting control
siRNA (Santa Cruz Biotechnology, Santa Cruz, Calif) in
serum-free medium that contained Lipofectamine Plus
(Invitrogen, Carlsbad, Calif). RIP/ mouse embryonic
fibroblasts were transiently transfected with myc-tagged
wild-type RIP or control vector, as described previously.10
Transfection efficiency was assessed by Western blot
analysis.
Stable Transfection
HSC-3 and UM-SCC-14A cells were transduced with ei-
ther RIP short hairpin RNA (RIP-shRNA) (sc44326-V),
SIRT3-shRNA (sc61555-vs; human), or scrambled-
shRNA (sc-108084; human; Santa Cruz Biotechnology)
lentiviral particles in 0.5 mL serum-free media and then
were selected in 10 lg/mL puromycin (sc-108071; Santa
Cruz Biotechnology) for an additional 10 days. Surviving
cell colonies were picked and propagated before they were
tested for RIP or SIRT3 expression using Western blot
analysis. It is noteworthy that, to avoid off-target effects,
SIRT3 lentiviral particles are designed by blasting the
mRNA accession number of SIRT3 against all the known
mRNA accession numbers of the same species to mini-
mize/ensure that there are no off-target effects. In addi-
tion, to further minimize off-target effects, the SIRT3-
shRNA lentiviral particles used in this study are from a
pool of concentrated, transduction-ready viral particles
containing 3 target-specific constructs that encode 19 to
25 nucleotides of shRNA designed to knock down gene
expression. Similar shRNA design strategies were used for
RIP shRNA lentiviral particle production.
Immunoblot Analysis
To evaluate the expression levels of RIP and SIRT3, cells
were treated as described above or in the figure legends,
washed once with phosphate-buffered saline, lysed in
radioimmunoprecipitation assay (RIPA) buffer (R0278;
Sigma Chemical Company, St. Louis, Mo) that contained
1% protease inhibitor cocktail (P8340; Sigma Chemical
Company), then kept on ice for 30 minutes. Lysates were
adjusted for protein concentration with the BCA protein
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assay kit (Bio-Rad, Hercules, Calif). Western blot analyses
were performed with various primary antibodies and
horseradish peroxidase-conjugated antirabbit or anti-
mouse immunoglobulin G antibodies, and blots were
developed with the ECL-Plus detection system (Pierce,
Rockford, Ill). Antibodies for RIP, SIRT3, and cleaved
caspase 3 were from Millipore (610459), Cell Signaling
Technology (2627; Beverly, Mass), and Santa Cruz Bio-
technology (7148), respectively. To demonstrate equal
protein loading, membranes were stripped and reprobed
with an anti-b-actin antibody (sc-1615; Santa Cruz
Biotechnology).
Anoikis-Resistant and Control Adherent Oral
Squamous Cell Carcinoma Cells
Anoikis-resistant oraspheres (UM-SCC-14A and HSC-3)
and adherent (UM-SCC-14A and HSC-3) OSCC cells
were prepared as previously reported.4 These OSCC cell
lines were selected because they represent the extremes of
RIP and SIRT3 expression among the OSCC cell lines
that we examined. These OSCC cells were developed by
maintaining cells under suspension conditions on polyhy-
droxyethylmethacrylate poly-HEMA)-coated plates (7.5
mg/mL in 95% ethanol; Sigma Chemical Company) for
6 days, where they survive anchorage withdrawal by form-
ing multicellular aggregate oraspheres. Adherent control
cells were maintained in culture medium as described
previously.
Immunodeficient Mouse Tumor Model
To examine the effects of anoikis-resistance and adherent
OSCC cells in vivo, UM-SCC-14A and SIRT3-sup-
pressed UM-SCC-14A cells and controls were grown in
anoikis-resistant and adherent conditions as described
above. Four-week-old athymic nude mice (NCr-nu/nu
strain; National Cancer Institute, Frederick, Md) were
anesthetized by intraperitoneal injection with 100 mg/kg
ketamine and 10 mg/kg xylazine. We used a murine floor-
of-mouth model, which we previously optimized to pro-
duce 4-mm to 5-mm tumors, corresponding to a palpable
tumor volume of 35 to 60 mm3, within approximately 2
to 4 weeks after injection of tumor cells.14,16 Anoikis-
resistant and adherent control UM-SCC-14A cells were
prepared to a final concentration of 1.0  106/0.05 mL
and injected submucosally into the floor of the mouth as
described previously.14 Six weeks after injection, the mice
were killed, and tumor volumes were measured by digital
caliper using the formula a  a  b/2, in which a is the
smaller dimension. Tumor tissues were then harvested,
rinsed in phosphate-buffered saline, and fixed overnight
in 10% buffered formalin. Tissues were paraffin-embed-
ded, sectioned, and processed for routine histopathologic
assessment with hematoxylin and eosin staining and for
SIRT3 and RIP immunostaining.
Apoptosis Cell Death Detection by
Enzyme-Linked Immunosorbent Assay
Apoptosis was measured in vitro using a DNA-fragmenta-
tion enzyme-linked immunosorbent assay according to
the manufacturer’s instructions (Roche Diagnostics, Indi-
anapolis, Ind).
Statistical Analysis
In general, values are expressed as means standard devi-
ations. Intergroup differences were determined by using a
2-way analysis of variance and a Scheffe multiple-compar-
ison test. Statistical significance was defined as P  .05.
For tissue microarray analyses, the McNemar test was
used to compare the 2 proportions, and the difference was
considered significantly different when P  .001. For the
in vivo studies, independent t tests with unequal variances
were used. All experiments were repeated at least 3 times.
RESULTS
SIRT3 and RIP Are Oppositely Expressed in Oral
Squamous Cell Carcinoma In Vivo
We recently reported that SIRT3 is overexpressed in
OSCC in vivo and in vitro compared with other sirtuins
and that its stable suppression reduces tumor burden in
vivo, implicating SIRT3 as a prosurvival and tumor-pro-
moting factor.14 In addition, we demonstrated that RIP
plays a critical role in OSCC cells by regulating anoikis
through its shuttling between the CD95/Fas death and
FAK survival signaling pathways, thus demonstrating that
RIP acts as a switch between life and death signals in
OSCC cells.10 Also, it is known that SIRT3 regulates cell
survival, metabolism, and tumorigenesis. Therefore, we
hypothesized that SIRT3 may engage in cross-talk with
RIP to regulate anoikis resistance and tumorigenesis in
OSCC cells. To test this hypothesis, we first evaluated the
native expression levels of SIRT3 and RIP in serial sec-
tions of OSCC tissue microarrays (TMAs). Our data
included 28 OSCC tongue samples in which SIRT3 and
RIP expression were evaluated and assessed as low (L) or
high (H) (Table 1). SIRT3 and RIP staining intensity
data from Table 1 are illustrated in Figure 1B. We already
knew that SIRT3 expression levels were elevated in
human OSCC14; however, the relative expression level of
RIP in these same tissues was not known. It is noteworthy
that observed opposite expression of SIRT3 and RIP in
OSCC tissues (Fig. 1A). In 86% of the samples in which
SIRT3 expression was high, 75% had low RIP expression
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(Fig. 1B, Table 1). Thus, 18 of 28 specimens (64%) had
opposite expression patterns for SIRT3 and RIP (P .05)
(Fig. 1A,B, Table 1).
SIRT3 and RIP Have Opposite Expression
Patterns in Oral Squamous Cell Carcinoma
In Vitro
Similarly, when we examined several OSCC cell lines
(HSC-3, OSCC-3, and UM-SCC-14A) for SIRT3 and
RIP expression, we again noted that SIRT3 expression lev-
els were the opposite of RIP expression levels in these cells
(Fig. 2A). Primary oral keratinocytes also had opposing
SIRT3 and RIP expression patterns; however, those cells
generally exhibited higher levels of RIP expression versus
SIRT3 expression (Fig. 2A). These findings again further
support the concept that RIP and SIRT3 exhibit a strong
negative correlation. To test this further, OSCC cell lines
(HSC-3 and UM-SCC-14A) were selected for further
experiments to determine whether RIP or SIRT3 regulate
each other and to examine the hierarchy of this potential
negative correlation. These OSCC cell lines were chosen
because they represent the extremes of SIRT3 and RIP
expression among the OSCC cell lines examined. Tran-
sient suppression of RIP effectively increased SIRT3
expression levels (Fig. 2B). However, stable suppression
of SIRT3 failed to alter RIP expression levels (Fig. 2C).
Furthermore, reconstitution of RIP in RIP null cells
down-regulated SIRT3 expression (Fig. 2D). This indi-
cated that SIRT3 was responsive to changes in RIP levels
but not the contrary, suggesting that RIP is a potential
upstream regulator of SIRT3.
Anoikis-Resistant Oral Squamous Cell
Carcinoma Oraspheres Express Higher Levels of
SIRT3 and Lower Levels of RIP
To examine the anoikis-resistant phenotype of OSCC
cells, an orasphere culture assay was used to study the
SIRT3 and RIP expression profile of OSCC cells in vitro.
We specifically developed anoikis-resistant cells and their
counterpart adherent controls (HSC-3 and UM-SCC-
14A cells), as described previously. Our data indicated
that anoikis-resistant OSCC cells in oraspheres maintain
cell survival and exhibit low levels of cleaved/active caspase
3 and DNA fragmentation or apoptosis (Fig. 3A-C). In
contrast, the single-cell counterpart of suspension cultures
undergoes apoptosis and exhibits high levels of cleaved/
active caspase 3 and DNA fragmentation (Fig. 3A-C).
The adherent counterpart control cells, like the cells in
oraspheres, also have low levels of cleaved/active caspase 3
and DNA fragmentation. It is noteworthy, however, that
the oraspheres express higher levels of SIRT3 and lower
levels of RIP compared with the adherent cells (Fig. 3D),
suggesting that OSCC cells escape anoikis-mediated cell
death in part by relying on SIRT3 survival signaling and
suppression of RIP death signaling pathways.
Anoikis-Resistant, Orasphere-Derived Oral
Squamous Cell Carcinoma Cells That Express
Higher Levels of SIRT3 and Lower Levels of RIP
Induce a Greater Tumor Burden
To investigate the in vivo relevance of our in vitro find-
ings, we also used a murine floor-of-mouth model that
mimics human OSCC.14,16,17 Mice were injected with
anoikis-resistant, orasphere-derived OSCC cells that
expressed higher SIRT3 levels (UM-SCC-14A cells) or
their adherent OSCC cell counterparts, which expressed
lower SIRT3 levels (Fig. 4). Our data indicated that mice
injected with anoikis-resistant, orasphere-derived cells ex-
hibit greater tumor burden compared with their adherent
counterparts (Fig. 4A, Table 2). Not only did the mice
injected with orasphere-derived cells develop significantly
larger tumors (12-fold difference in size; P  .027), but
they also developed more tumors (9 of 10 mice developed
Table 1. The Expression Profile of Receptor-Interacting




Sample No. Section No. Sex Age, y RIP SIRT3
1 A1 Man 57 Low High
2 A6 Woman 35 High High
3 A7 Man 78 Low High
4 A9 Woman 39 Low Low
5 A10 Woman 46 Low High
6 B3 Woman 57 Low High
7 B4 Woman 36 Low High
8 B8 Woman 47 High High
9 B9 Woman 63 Low Low
10 B10 Man 56 Low Low
11 C2 Woman 55 Low High
12 C3 Man 76 Low High
13 C4 Woman 50 Low High
14 C6 Man 55 High High
15 C9 Man 60 Low High
16 D1 Man 64 Low High
17 D2 Woman 52 Low High
18 D3 Woman 50 Low High
19 D4 Woman 46 Low High
20 D5 Woman 45 Low High
21 D6 Man 35 Low High
22 D7 Woman 46 High High
23 D8 Woman 48 High Low
24 E3 Man 60 High High
25 E4 Man 37 Low High
26 E6 Man 60 Low High
27 E8 Man 60 High High
28 E10 Man 73 Low High
Abbreviations: RIP, receptor-interacting protein; SIRT3, sirtuin-3.
a Staining intensity was graded as low or high.
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tumors) compared with 2 of 8 mice that were injected
with adherent control cells (Table 2) (P  .001) Histo-
logic examination of tumors dissected from mice injected
with orasphere-derived cells revealed a highly disorganized
histologic pattern of invasive epithelial islands with kera-
tin pearl formation, nuclear pleomorphism, hyperchro-
matism, and increased nuclear-to-cytoplasmic ratios
compared with their control counterparts (Fig. 4B). These
‘‘aggressive’’ tumors also had high levels of SIRT3 expres-
sion and low levels of RIP expression (Fig. 4B). In 80% of
the samples with high SIRT3 expression, 78% had low
RIP expression (Fig. 4C). In contrast, the few tumors that
emerged in mice that were injected with adherent control
cells revealed a tendency toward a regularly organized his-
tologic pattern of epithelial islands and a relatively lower
level of SIRT3 expression (data not shown). These data
support our in vitro findings and those of others6,7 indi-
cating that anoikis-resistant cells induce a greater tumor
Figure 2. Receptor-interacting protein (RIP) may be an upstream, negative regulator of sirtuin-3 (SIRT3). (A) Immunoblots reveal
RIP and SIRT3 levels in normal human keratinocytes and in oral squamous cell carcinoma (OSCC) cells (HSC-3, OSCC-3, and UM-
SCC-14A) that were plated for 1 day. b-Actin served as a loading control. (B) Immunoblots reveal RIP and SIRT3 levels after trans-
fection with control small interfering RNA (Ctl-siRNA) or with RIP-siRNA (25 nM or 50 nM) in HSC-3 cells for 30 hour. (C) Immu-
noblots reveal SIRT3 and RIP levels after stable SIRT3 suppression using lentiviral particles (scrambled controls [Scr-shRNA] or
SIRT3-shRNA) in UM-SCC-14A cells. (D) Immunoblots reveal RIP and SIRT3 levels after transfection with wild-type, v-myc myelo-
cytomatosis viral oncogene homolog (Myc)-tagged RIP (Myc-RIP) in RIP null cells (RIP/) for 30 hours.
Figure 1. Receptor-interacting protein (RIP) expression has an opposite relation to sirtuin-3 (SIRT3) expression in oral squamous
cell carcinoma (OSCC). (A) RIP and SIRT3 expression in OSCC tumor microarray specimens are illustrated. H&E indicates hema-
toxylin and eosin staining. Scale bars ¼ 200 lm in low-magnification photomicrographs (Top), 50 lm in high-magnification pho-
tomicrographs (Bottom). (B) This chart illustrates the percentage of OSCC serial tongue tissue sections that expressed RIP and
SIRT3 according to immunohistochemical staining. Staining intensity was graded as either high or low. The McNemar test was
used to compare the 2 proportions, which differed significantly (P  .001).
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Figure 3. Oral squamous cell carcinoma (OSCC) cells, as they become anoikis resistant, have increased sirtuin-3 (SIRT3) expres-
sion as their receptor-interacting protein (RIP) expression decreases. (A) These are phase-contrast images of OSCC cells (HSC-3
and UM-SCC-14A) that were cultured under adherent conditions or suspension conditions for 6 days, when oraspheres and single
cells were separated for analysis. (B,C) Immunoblots reveal (B) cleaved/active caspase 3 expression and (C) the fold change in
DNA fragmentation for adherent cells, oraspheres, and single cells. An asterisk indicates P  .05. (D) Immunoblots reveal RIP and
SIRT3 expression in adherent cells and oraspheres. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
Figure 4. Anoikis-resistant oral squamous cell carcinoma (OSCC) cells induce greater tumor burden in mice. (A) These images
show tumor-bearing mice 6 weeks after injection with adherent or orasphere/anoikis-resistant UM-SCC-14A cells. Shown are
(Top) a superficial tumor and (Bottom) a dissected tumor. (B) Representative orasphere-derived tumor sections were stained
with hematoxylin and eosin (H&E) and were immunostained with antibodies for RIP and SIRT3. (C) This chart illustrates the per-
centage of tissue specimens that expressed RIP and SIRT3 in orasphere-derived tumor sections, as determined by immunohisto-
chemical staining. Staining intensity was graded as either high or low. The McNemar test was used to compare the 2 proportions,
which differed significantly (P  .001).
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burden and a more aggressive phenotype in OSCC. In
addition, these cells seem to rely, at least in part, on
SIRT3 up-regulation and RIP down-regulation to main-
tain their survival and aggressive phenotype. Thus, high
SIRT3 expression and low RIP expression may impart re-
sistance to anoikis-mediated cell death.
SIRT3 Up-Regulation and RIP Down-Regulation
Regulate the Fate of Oral Squamous Cell
Carcinoma Cells in Anoikis Conditions
To further validate the importance of SIRT3 and RIP in
regulating the fate of OSCC cells under suspension/anoi-
kis conditions, stable cell clones of SIRT3-shRNA (Clone
2) and scrambled-shRNA (Clone 1) were examined under
adherent and suspension conditions. Our data indicate
that, under suspension conditions, cells that express
SIRT3-shRNA can no longer form oraspheres, maintain
their survival, or escape anoikis, unlike cells that express
scrambled-shRNA (Fig. 5A), confirming the role of
SIRT3 in anoikis resistance. In addition, cells in suspen-
sion conditions that stably express SIRT3-shRNA (ora-
spheres and single cells) had increased levels of RIP
expression and cleaved/active caspase 3 and had higher
levels of DNA fragmentation compared with cells that
expressed SIRT3-shRNA and were grown in adherent
conditions or cells that expressed scrambled-shRNA and
were grown in adherent or suspension conditions (Fig.
5B-D). Furthermore, stable suppression of SIRT3 inhib-
its anoikis resistance and reduces tumor incidence in vivo
(Fig. 5E). The higher RIP expression present in the cells
transduced with SIRT3-shRNA in suspension conditions
likely represents the single-cell fraction present in this
mixed culture system. Furthermore, RIP overexpression
promotes anoikis,10 and RIP suppression inhibits anoikis,
caspase 3 activation, and DNA fragmentation (Fig. 6A-
D). These data demonstrate that SIRT3 and RIP are at
opposite ends of anoikis resistance in OSCC cells and that
SIRT3 is required for escaping anoikis and for acquisition
of an anoikis-resistant phenotype. On the basis of these
findings, we propose a model for the role of SIRT3 in
regulating survival and anoikis resistance (Fig. 7).
DISCUSSION
Cancers that are prone to metastases possess an anoikis-re-
sistant phenotype, thereby acquiring more aggressive
behavior and resistance to treatment, and contributing to
poor survival rates. This reportedly is the case for several
cancers, such as prostate, hepatic, and oral cancers.6,18,19
Thus, understanding the molecular mechanisms underly-
ing an anoikis-resistant phenotype will help identify new
potential therapeutic targets to treat aggressive cancer.
Our previous report that RIP can shuttle between
survival and death-signaling pathways under anoikis con-
ditions in oral cancer10 demonstrates the important role
of RIP in controlling the fate of OSCC cells under anoikis
conditions. In addition, our recent finding that OSCC
cells rely on SIRT3 to maintain their survival and aggres-
sive behavior also suggests an important role for SIRT3
in OSCC tumorigenesis. Specifically, we observed that
SIRT3 down-regulation decreased OSCC cell prolifera-
tion and survival, enhanced the sensitivity of OSCC
radioresistant and chemoresistant cells to both radiothera-
peutic and chemotherapeutic treatments, and reduced
tumor burden in vivo.14 In the current study, we demon-
strate for the first time a link between anoikis resistance
and SIRT3 in oral cancer and its potential cross-talk with
RIP, thus highlighting 1 important new mechanism by
which SIRT3 can modulate OSCC progression.
Our data demonstrate that SIRT3 and RIP have op-
posite expression levels in OSCC and that OSCC cells
escape anoikis by forming multicellular aggregates or ora-
spheres to maintain their survival compared with single
cells, which undergo anoikis-mediated cell death. It is
noteworthy that OSCC cells appear to rely, at least in
part, on altering their SIRT3 and RIP levels to escape
anoikis. Furthermore, OSCC cells that stably expressed
down-regulated levels of SIRT3 failed to form oraspheres
and, thus, experienced significantly more anoikis, suggest-
ing a critical role for SIRT3 in regulating anoikis resist-
ance in OSCC cells. In agreement with our findings, lung
adenocarcinoma cells form spheroids or aggregates that
express E-cadherin and phosphorylated Src (p-Src) to
maintain their survival under suspension conditions.
Thus, it was reported that Src is an essential regulator in
the development of anoikis resistance in lung
Table 2. Tumor Volumes for Mice Injected With
UM-SCC-14A Human Oral Squamous Cell Carcinoma Cells
Tumor Volume, mm3




3 No tumor 22.86
4 No tumor 864
5 No tumor 243.3
6 No tumor 252
7 No tumor 215.66
8 No tumor 138.16
9 — 83.49
10 — No tumor
Mean volume 25.42a 311.84a
a Statistical analysis: Independent t test with unequal variances P  .027
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Figure 6. Receptor-interacting protein (RIP) suppression inhibits anoikis, caspase-3 activation, and DNA fragmentation. (A) Im-
munoblots reveal RIP and sirtuin-3 (SIRT3) levels after stable RIP suppression using lentiviral particles (scrambled short hairpin
RNA [Scr-shRNA] or RIP-shRNA). (B) These are phase-contrast images of HSC-3 cells that were transduced with Scr-shRNA or
RIP-shRNA (viral transduction and puromycin selection for 10 days) then cultured under adherent conditions or suspension con-
ditions (oraspheres plus single cells) for 6 days. (C,D) Immunoblots reveal (C) cleaved/active caspase 3 expression and (D) the
fold change in DNA fragmentation under adherent conditions or suspension conditions (oraspheres plus single cells) for 6 days.
Agg indicates aggregates. An asterisk indicates P  .05.
Figure 5. Sirtuin-3 (SIRT3) suppression blocks orasphere formation, inhibits anoikis resistance, and reduces tumor incidence in vivo.
(A) These are phase-contrast images of UM-SCC-14A cells that were transduced with scrambled short hairpin RNA (Scr-shRNA) or
with SIRT3-shRNA (viral transduction and puromycin selection for 10 days) then cultured under adherent conditions or suspension
conditions (oraspheres plus single cells) for 6 days. (B,C) Immunoblots reveal (B) receptor-interacting protein (RIP) and SIRT3 lev-
els and (C) and cleaved/active caspase 3 levels in scrambled controls or SIRT3-suppressed UM-SCC-14A cells that were cultured
under adherent conditions or suspension conditions (oraspheres/anoikis-resistant) for 6 days. (D) The fold change in DNA fragmen-
tation is illustrated under adherent conditions or suspension conditions (oraspheres plus single cells) for 6 days. An asterisk indi-
cates P  .05. (E) The percentage of tumor incidence is illustrated in nude mice that were injected with SIRT3-suppressed UM-SCC-
14A cells (SIRT3-shRNA) or scrambled controls (Scr-shRNA) under adherent conditions or suspension conditions (oraspheres
[Oras] plus single cells) after 6 weeks. Tumor incidence is indicated relative to the number of animals in each group. [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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adenocarcinomas.20 It also was reported that mammo-
sphere cultures of breast cancer cells from pleural effusions
were tumorigenic and induced tumors in severe com-
bined-immunodeficiency (SCID) mice.5 Furthermore, a
recent report demonstrated that ovarian cancer spheroids
used integrin-dependent and talin-dependent activation
of myosin and traction forces to promote the displace-
ment of mesothelial cells from underneath a tumor cell
spheroid.21 In summary, multiple studies have supported
the concept that spheroid formation promotes cancer cell
survival and tumorigenesis.
Limited studies have examined the role of anoikis-
resistance in OSCC progression and aggressive behavior
using in vivo models. One study used a tongue oral cancer
mouse model to demonstrate that anoikis-resistant
OSCC cells were more aggressive than their anoikis-sensi-
tive counterparts, and mice injected with these cells had
shorter survival (17 days vs 30 days) compared with mice
injected with anoikis-sensitive OSCC cells.6 In our cur-
rent study, we used a different in vivo model, a murine
floor-of-mouth model that mimics human OSCC,16,17
and demonstrated that anoikis-resistant OSCC cells,
which express increased levels SIRT3 and decreased levels
of RIP, exhibit greater tumor burden compared with their
adherent OSCC counterparts. These data further support
our previous in vivo findings, in which OSCC cells with
stably suppressed levels of SIRT3 injected in the samemu-
rine floor-of-mouth model exhibited reduced tumor bur-
den compared with controls.14 It is noteworthy that our
current data indicate that suppressing SIRT3 also blocks
the acquisition of an anoikis-resistant phenotype in vitro
and in vivo. Thus, our current data support the finding
that SIRT3 and RIP are oppositely expressed in OSCC
anoikis-resistant cells, and this enables these cells to escape
anoikis and take on a more aggressive phenotype. Because
this short, 6-week, floor-of-mouth model is not optimal
for the examination of oral metastases, other animal
models of metastases are needed to examine this process
specifically in future studies.
RIP can localize to the cytoplasm22,23 or the mito-
chondria.24,25 In addition, although there is debate about
the subcellular localization of SIRT3, most reports sup-
port a mitochondrial localization for SIRT3.26-34 In the
mitochondria, RIP inhibits adenosine diphosphate/aden-
osine triphosphate (ADP/ATP) exchange by modulating
adenine nucleotide translocate (ANT). This modulation
results in the loss of ANT and cyclophilin-D interactions,
reduction in ATP levels, and induction of cell death, and
it implicates RIP in mitochondrial-mediated cell death.24
Our data demonstrate that SIRT3 and RIP are oppositely
expressed in OSCC and that they regulate anoikis-resist-
ance in OSCC cells. Because SIRT3, a mitochondrial sir-
tuin, can localize to the mitochondrial matrix, and RIP
can localize to the mitochondrial outer membrane,24,25
this suggests that these 2 molecules may interact indirectly
through other molecules in the context of regulating anoi-
kis resistance in OSCC cells. One putative molecule
would be cyclophilin-D. It is noteworthy that RIP appears
to negatively regulate cyclophilin-D, thus inducing
mitochondrial-mediated cell death. Conversely, SIRT3
interacts and deacetylates the regulatory component of
mitochondrial permeability transition pore (mPTP),
cyclophilin-D, thus preventing mitochondrial dysfunc-
tion and cardiac hypertrophy.35 This supports the idea
that RIP and SIRT3 play opposite roles in regulating cell
death and survival through a common third molecule,
cyclophilin-D.
Furthermore, some evidence suggests that RIP is
critical for regulating reactive oxygen species (ROS)
mechanisms,36,37 and it is well known that SIRT3 also is
functionally important in ROS regulation.15,38,39 There-
fore, RIP and SIRT3 may be functionally related through
ROS regulation pathways in the context of anoikis resist-
ance. However, whether this relation is mediated by ROS
modulation or by indirect interactions through a third
molecule between SIRT3 and RIP, such as cyclophilin-D,
is an area that is currently under investigation by our
group.
There is also a debate in the literature regarding the
role of SIRT3 in cancer.15 Although some reports support
a prosurvival role for SIRT3 in cancer,14,15,40-43 others
support a tumor suppressor role for SIRT3.44-46 Our pre-
vious and current studies demonstrate that SIRT3 plays a
prosurvival role in oral cancer; that SIRT3 assists in
Figure 7. A working model of anoikis resistance is illustrated.
Anoikis-resistant cells form multicellular aggregates (ora-
spheres) that express higher sirtuin-3 (SIRT3) levels as their
receptor-interacting protein (RIP) expression decreases,
thereby promoting their survival and more aggressive pheno-
type in oral squamous cell carcinoma (OSCC) development
and progression.
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chemoresistance and radioresistance; and that, by promot-
ing anoikis resistance, SIRT3 mediates a more aggressive
tumorigenic phenotype.
In summary, our studies reveal for the first time a
novel role for SIRT3 as a modulator of anoikis resistance
in oral cancer through a potential negative relation with
RIP. This work further enriches our understanding of the
role of SIRT3 in the regulation of oral cancer tumorigene-
sis and implicates SIRT3 as new potential therapeutic
target to treat oral cancer.
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